BiotechTube

AZD8566 + AZD8566 IV carbon labelled

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Healthy Volunteer Study

Conditions

Healthy Volunteer Study

Trial Timeline

Mar 1, 2009 → Apr 1, 2009

NCT ID
NCT00866385

About AZD8566 + AZD8566 IV carbon labelled

AZD8566 + AZD8566 IV carbon labelled is a phase 1 stage product being developed by AstraZeneca for Healthy Volunteer Study. The current trial status is completed. This product is registered under clinical trial identifier NCT00866385. Target conditions include Healthy Volunteer Study.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT00866385Phase 1Completed

Competing Products

20 competing products in Healthy Volunteer Study

See all competitors
ProductCompanyStageHype Score
AZD0837AstraZenecaPhase 1
33
ValsartanNovartisPhase 1
33
CSL112 + PlaceboCSLPhase 1
32
UT-15CUnited TherapeuticsPhase 1
30
VNA-318 + PlaceboBiotrialPhase 1
25
Open-label TRV734 125 mg + TRV734 blinded + Oxycodone IR 10 mg + PlaceboTrevenaPhase 1
25
TRV130 + Moxifloxacin + PlaceboTrevenaPhase 1
25
Radiolabeled TRV130TrevenaPhase 1
25
TRV130A + Dextrose in WaterTrevenaPhase 1
25
TRV734TrevenaPhase 1
25
ALT02 + EU-licensed Herceptin + US-licensed HerceptinAlteogenPhase 1
33
ENZ215 + EU Sourced Prolia + US Sourced ProliaAlkem LaboratoriesPhase 1
33
KPL-404Kiniksa PharmaceuticalsPhase 1
28
MORF-057 + Placebo for MORF-057Eli LillyPhase 1
33
Propranolol + PseudoephedrineEli LillyPre-clinical
23
LY2157299Eli LillyPhase 1
33
Lasmiditan + PlaceboEli LillyPhase 1
33
LY3015014 + PlaceboEli LillyPhase 1
33
LOXO-783Eli LillyPhase 1
33
LY2541546 - IV + LY2541546 - SC + PlaceboEli LillyPhase 1
33

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85